Trial record 1 of 1 for:    NCT02504489 | Recruiting Studies
Previous Study | Return to List | Next Study

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02504489
Recruitment Status : Recruiting
First Posted : July 22, 2015
Last Update Posted : March 20, 2017
Information provided by (Responsible Party):
BeyondSpring Pharmaceuticals Inc.

Brief Summary:

The primary purpose of the study is to compare the overall survival of NSCLC patients receiving second- or third-line chemotherapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D Arm) for advanced or metastatic disease.

Secondary purposes of the study are:

  1. To compare the neutropenia (frequency, severity and clinical sequelae), duration of response, quality of life, response rate and progression free survival in patients with NSCLC treated with DP to patients treated with D as second- or third-line chemotherapy for advanced or metastatic disease; and
  2. To compare the safety and adverse event profiles of DP to D respectively, as well as dose delays, dose modifications, and/or dose discontinuation of docetaxel due to safety concerns in the two treatment arms.
  3. To evaluate population pharmacokinetics in patients enrolled in China and western countries (US and Australia).

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: Docetaxel + Plinabulin (DP) Drug: Docetaxel (D) Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 550 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Study Start Date : June 2016
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Docetaxel (D)
A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Routine antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
Drug: Docetaxel (D)
Docetaxel 75 mg/m2 IV
Other Name: Taxotere
Experimental: Docetaxel + Plinabulin (DP)

The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 30 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On day 8, plinabulin infusion will be repeated.

On Day 1, no pre-medication will be routinely administered for plinabulin infusion. Anti-emetics may be prescribed as indicated according to institutional guidelines for chemotherapy. On Day 8, antiemetic prophylaxis may be administered prior to plinabulin infusion. For Cycle 1 Day 8 only, Zofran® (ondansetron) is prohibited due to its interference with QTc study.

Drug: Docetaxel + Plinabulin (DP)
Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Other Name: BPI-2358, NPI-2358
Drug: Docetaxel (D)
Docetaxel 75 mg/m2 IV
Other Name: Taxotere

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Approximately 2 years after study initiation ]

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Approximately 2 years after study initiation. ]
  2. Response rate [ Time Frame: Approximately 2 years after study initiation. ]
  3. Duration of response [ Time Frame: Approximately 2 years after study initiation. ]
  4. Incidence and severity of treatment-emergent adverse events [ Time Frame: Approximately 2 years after study initiation. ]
  5. Incidence of serious adverse events. [ Time Frame: Approximately 2 years after study initiation. ]
  6. Incidence of discontinuation of study treatment due to safety reasons [ Time Frame: Approximately 2 years after study initiation. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. ECOG performance status ≤ 2.
  2. Histopathologically or cytologically confirmed NSCLC.
  3. Disease progression during or after treatment with one or two treatment regimen(s). Treatment regiments can be chemotherapy or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV). Modification of regimen to manage toxicity with a different drug does not constitute a new regimen. Maintenance therapy following platinum-based chemotherapy is not considered as a separate regimen. Adjuvant chemotherapy and/or chemoradiation for early stage disease do not count as prior chemotherapy. Prior radiation and/or PD-1/PD-L1 immunotherapy is not exclusionary. Prior treatment for advanced or metastatic disease must have included a platinum-based regimen.
  4. At least 1 lesion > 3 cm in longest diameter in lung parenchyma.
  5. patients with nonsquamous NSCLC must have been tested for EGFR exon 19 deletion and Exon 21 L858R substitution mutation. Patients without EGFR sensitizing mutations are eligible and must have progressed on platinum-containing chemo.
  6. Patients with active brain metastasis or leptomeningeal involvement with brain metastases who are asymptomatic, and whose lesions by imaging are at least stable and without interim development of new lesions for at least 4 weeks may be enrolled. Patients who require continued therapy with steroid medication for management for their brain metastases are eligible; dosing must be stable for at least 4 weeks prior to enrollment
  7. All AE's of prior chemo., surgery, or radiotherapy, must have resolved to CTCAE v 4.03 Grade 2, except for neurological AE's that must have resolved to Grade 1.
  8. The following laboratory results ≤14 days prior to study drug admin:

    Hgb 9 g/dL independent of transfusion or growth factor support; absolute neutrophil count 1.5x109/L independent of growth factor support; platelet count 100x109/L independent of transfusion or growth factor support; Serum total bilirubin 1.5 times the upper limit normal (ULN), unless the patient has a diagnosis of Gilbert's disease then serum bilirubin 3.0 times ULN;

  9. AST & ALT 2.5 x ULN(1.5 x ULN if alkaline phosphatase is > 2.5 x ULN), and serum creatinine 1.5 x ULN.
  10. Life expectancy >12 weeks.
  11. Signed informed consent.

EXCLUSION CRITERIA: Patients with any of the following:

  1. Administration of chemo, biological, immunotherapy, radiotherapy or investigational agent (therapeutic or diagnostic) ≤3 weeks prior to receipt of study medication. Major surgery, other than diagnostic surgery, ≤4 weeks before first study drug admin.
  2. Significant cardiac history:

    History of myocardial infarction or ischemic heart disease ≤1 year before 1st study drug administration; uncontrolled arrhythmia; history of congenital QT prolongation; ECG findings consistent with acute ischemic heart disease; NYHA Class III-IV cardiac disease; & uncontrolled hypertension: BP consistently >150 mm Hg systolic & 100 mm Hg diastolic in spite of antihypertensive medication

  3. Patients who have received prior treatment with docetaxel, paclitaxel or other taxane preparation for advanced or metastatic disease.
  4. Prior transient ischemic attack or cerebrovascular accident. Neurologic toxicities > Grade 2.
  5. History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable.) History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
  6. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
  7. Known infection with human immunodeficiency virus (HIV) or active hepatitis A, B, or C.
  8. Known prior hypersensitivity reaction to any product containing polysorbate 80, Polyoxyethylene 15 hydroxystearate/Macrogol 15 Hydroxystearate (Solutol HS 15).
  9. Female subject who is pregnant or lactating
  10. Second malignancy unless in remission for >5 years. (Non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent is not exclusionary.)
  11. Medical conditions that would impose excessive patient risk. Examples: Infection requiring parenteral anti infective treatment, liver failure, altered mental status or psychiatric condition that would interfere with the understanding of the informed consent.
  12. Unwilling or unable to comply with protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02504489

Contact: Lan Huang, Ph.D. 1 (646)528-4184
Contact: Gordon L Schooley, Ph.D. 1 (858) 353-0704

United States, California
Pacific Cancer Medical Center, Inc. Recruiting
Anaheim, California, United States, 92801
Contact: Elizabeth Brown   
Principal Investigator: Veena Charu, MD         
U. California San Diego (UCSD) Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Lyudmila A. Bazhenova, M.D.    858-822-6100   
UC San Diego Moores Cancer Center Recruiting
La Jolla, California, United States, 92093
Contact: Justine Panian    858-534-7585   
Principal Investigator: Lyudmila Bazhenova, MD         
NICR: Synergy Hematology Oncology Recruiting
Los Angeles, California, United States, 90048
Contact: Anton Akulov    323-725-0657   
Principal Investigator: Levon Qasabian, MD         
Innovative Clinical Research Institute Recruiting
Whittier, California, United States
Contact: Kirsten Bettino   
Principal Investigator: Eddie Thara, MD         
United States, Colorado
Memorial Health Care System Recruiting
Colorado Springs, Colorado, United States
Contact: Caralyn Hutchens   
Principal Investigator: Robert Hoyer, MD         
United States, Georgia
Peachtree Hematoloy-Oncology Consultants, PC Recruiting
Atlanta, Georgia, United States
Contact: Ann Johnston   
Principal Investigator: Trevor Feinstein, MD         
United States, Illinois
Carle Cancer Center Recruiting
Urbana, Illinois, United States, 61801
Contact: Joshua Ward   
Principal Investigator: Krishna Vasireddy, DO         
United States, Kentucky
University of Louisville-Brown Cancer Center Recruiting
Louisville, Kentucky, United States, 40202
Contact: Goetz Kloecker, MD   
Contact: Karen Carter, RN   
United States, Mississippi
Hattiesburg Clinic Hematology/Oncology Recruiting
Hattiesburg, Mississippi, United States, 39401
Contact: Tammy McBeth    601-288-2495   
Principal Investigator: John Hrom, MD         
United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Nagia A Karim, MD   
Toledo Cancer Center Recruiting
Toledo, Ohio, United States, 43623
Contact: Rex B Mowat, MD    419-473-3561      
Contact: Jessica Ciesler, RN    419-473-3561      
United States, Tennessee
Cookeville Regional Medical Center Cancer Center Recruiting
Cookeville, Tennessee, United States, 61801
Contact: Linda Moore   
Principal Investigator: Paul Jacquin, MD         
Sponsors and Collaborators
BeyondSpring Pharmaceuticals Inc.
Principal Investigator: Lyudmila A Bazhenova, M.D. U. California San Diego (UCSD) Moores Cancer Center 858-822-6100

Additional Information:
Responsible Party: BeyondSpring Pharmaceuticals Inc. Identifier: NCT02504489     History of Changes
Other Study ID Numbers: BPI-2358-103
First Posted: July 22, 2015    Key Record Dates
Last Update Posted: March 20, 2017
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents